3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Conditions
Leukemia, Myeloid, Acute
80
Leukemia
31
Myelodysplastic Syndromes
19
Leukemia, Myelomonocytic, Acute
14
Leukemia, Monocytic, Acute
14
Leukemia, Erythroblastic, Acute
14
Leukemia, Megakaryoblastic, Acute
13
Congenital Abnormalities
12
Recurrence
6
Leukemia, Promyelocytic, Acute
6
Anemia, Refractory, with Excess of Blasts
6
Leukemia, Eosinophilic, Acute
5
Leukemia, Basophilic, Acute
5
Leukemia, Myelomonocytic, Chronic
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasm, Residual
2
Myeloproliferative Disorders
2
Leukemia, Myelomonocytic, Juvenile
2
Sarcoma, Myeloid
1
Leukemia, Myeloid
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Disease Progression
1
Disease
1
Blast Crisis
1
Interventions
Cyclophosphamide
22
blinatumomab
18
Cytarabine
15
fludarabine
13
Azacitidine
12
venetoclax
10
fludarabine phosphate
10
Rituximab
8
Lenalidomide
7
Dexamethasone
7
Methotrexate
6
Daunorubicin
6
Mercaptopurine
5
daratumumab
4
Whole-Body Irradiation
4
Vincristine
4
Melphalan
4
Idarubicin
4
Etoposide
4
Busulfan
4
pembrolizumab
3
obinutuzumab
3
Radiotherapy
3
Maintenance
3
Immunotherapy, Adoptive
3
Imatinib Mesylate
3
Granulocyte Colony-Stimulating Factor
3
Drug Therapy
3
Cladribine
3
Asparaginase
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasm, Residual
×
Gemtuzumab
×
Clear all
NCT05904106
2024-12-02
VINCENT
Technische Universität Dresden
Phase 2
Recruiting
146 enrolled
NCT02724163
2021-10-08
Myechild01
University of Birmingham
Phase 3
Recruiting
700 enrolled